These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis. Wiesemann E; Klatt J; Wenzel C; Heidenreich F; Windhagen A Clin Exp Immunol; 2003 Sep; 133(3):454-60. PubMed ID: 12930374 [TBL] [Abstract][Full Text] [Related]
3. Effect of glatiramer acetate (Copaxone) on CD4+CD25high T regulatory cells and their IL-10 production in multiple sclerosis. Putheti P; Soderstrom M; Link H; Huang YM J Neuroimmunol; 2003 Nov; 144(1-2):125-31. PubMed ID: 14597106 [TBL] [Abstract][Full Text] [Related]
4. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype. Dhib-Jalbut S; Chen M; Said A; Zhan M; Johnson KP; Martin R J Neuroimmunol; 2003 Jul; 140(1-2):163-71. PubMed ID: 12864985 [TBL] [Abstract][Full Text] [Related]
5. Effect of combined IFNbeta-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis. Dhib-Jalbut S; Chen M; Henschel K; Ford D; Costello K; Panitch H Mult Scler; 2002 Dec; 8(6):485-91. PubMed ID: 12474988 [TBL] [Abstract][Full Text] [Related]
6. Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. Hussien Y; Sanna A; Söderström M; Link H; Huang YM J Neuroimmunol; 2001 Dec; 121(1-2):102-10. PubMed ID: 11730946 [TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate (copolymer-1)-specific, human T cell lines: cytokine profile and suppression of T cell lines reactive against myelin basic protein. Dabbert D; Rösner S; Krämer M; Schöll U; Tumani H; Mäder M; Weber F Neurosci Lett; 2000 Aug; 289(3):205-8. PubMed ID: 10961665 [TBL] [Abstract][Full Text] [Related]
9. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta1a or glatiramer acetate compared with untreated patients. Jansson A; Ernerudh J; Kvarnström M; Ekerfelt C; Vrethem M Mult Scler; 2003 Oct; 9(5):440-5. PubMed ID: 14582766 [TBL] [Abstract][Full Text] [Related]
10. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Khoury SJ; Healy BC; Kivisäkk P; Viglietta V; Egorova S; Guttmann CR; Wedgwood JF; Hafler DA; Weiner HL; Buckle G; Cook S; Reddy S Arch Neurol; 2010 Sep; 67(9):1055-61. PubMed ID: 20837847 [TBL] [Abstract][Full Text] [Related]
11. Human and murine CD4 T cell reactivity to a complex antigen: recognition of the synthetic random polypeptide glatiramer acetate. Duda PW; Krieger JI; Schmied MC; Balentine C; Hafler DA J Immunol; 2000 Dec; 165(12):7300-7. PubMed ID: 11120865 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of immunomodulation by glatiramer acetate. Gran B; Tranquill LR; Chen M; Bielekova B; Zhou W; Dhib-Jalbut S; Martin R Neurology; 2000 Dec; 55(11):1704-14. PubMed ID: 11113226 [TBL] [Abstract][Full Text] [Related]
14. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients. Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047 [TBL] [Abstract][Full Text] [Related]
15. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins. Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900 [TBL] [Abstract][Full Text] [Related]
16. Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment. Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V J Neurol Neurosurg Psychiatry; 2003 Jan; 74(1):123-6. PubMed ID: 12486283 [TBL] [Abstract][Full Text] [Related]
17. In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Schmied M; Duda PW; Krieger JI; Trollmo C; Hafler DA Clin Immunol; 2003 Mar; 106(3):163-74. PubMed ID: 12706402 [TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. Vieira PL; Heystek HC; Wormmeester J; Wierenga EA; Kapsenberg ML J Immunol; 2003 May; 170(9):4483-8. PubMed ID: 12707324 [TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis: expression of CD1a and production of IL-12p70 and IFN-gamma by blood mononuclear cells in patients on combination therapy with IFN-beta and glatiramer acetate compared to monotherapy with IFN-beta. Hussien Y; Sanna A; Söderström M; Link H; Huang YM Mult Scler; 2004 Feb; 10(1):16-25. PubMed ID: 14760948 [TBL] [Abstract][Full Text] [Related]
20. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]